Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
MICIN is a medical technology company based in Tokyo, Japan, with businesses spanning online healthcare, digital solutions for clinical development, digital therapeutics, and insurance. It serves medical institutions, pharmacies, pharmaceutical companies/clinical trial stakeholders, and patients. Its core goal is to make healthcare connections more convenient through technology and to create new treatment and lifestyle options based on health and medical data.
Its online medical service “curon/クロン” lets patients use a smartphone, computer, or tablet to complete appointments, medical questionnaires, consultations, payments, and procedures for delivery of in-hospital prescription medications. Doctors can also start using the service from a PC or tablet. For pharmacies, “クロンお薬サポート” supports online medication guidance, credit card payments, and delivery. For outpatient visits, “クロンスマートパス” covers reception, billing, prescription pickup, and notifications when dispensing is complete, reducing time spent waiting in line. Its clinical development business “MiROHA” includes online consultations, eConsent electronic informed consent, and eSource data digitization, making it suitable for decentralized clinical trials. In digital therapeutics, MedBridge focuses on helping patients build self-care habits and improving the efficiency of communication between patients and healthcare providers.
Publicly available information is limited. For medical institutions, the online consultation service has an initial setup fee and monthly fee of 0 yen. For medical institutions, クロンスマートパス has no implementation fee, monthly fee, or credit card payment processing fee. Other offerings such as MiROHA, MedBridge, and the insurance business do not disclose packages or billing models, so enterprise buyers will still need to request a quote.
Its strengths are broad coverage across healthcare scenarios, with products spanning consultations, pharmacies, clinical trials, and digital therapeutics. Its online consultation service has been available since 2016, giving it relatively early market experience. Some products also lower the adoption barrier for medical institutions. On the security side, patient login supports Passkey and passwordless multi-factor authentication, which is a plus. The main drawbacks are that public materials do not explain key enterprise software procurement items such as APIs, role-based permissions, system integration, SLAs, compliance certifications, and data residency. Pricing transparency is also limited.
MICIN is best suited to local Japanese medical institutions, pharmacies, pharmaceutical companies, clinical trial organizations, and healthcare providers looking to improve follow-up visits, medication guidance, and outpatient billing experiences. Chinese organizations evaluating it should pay particular attention to Japanese healthcare compliance fit, cross-border data issues, language support, local payments, and system integration capabilities.
The available materials do not provide information on access from mainland China, network reachability, or localized deployment. This should be considered unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on micin.jp official site.
micin.jp is an Japan Health provider. TG4G tracks its product information, an overall rating of 5.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach micin.jp directly.